Original Title: Transcatheter Aortic Valve Implantation for Paradoxical Low-Flow Low-Gradient Aortic Stenosis Patients. Reference: Nicolas Debry et al. Catheter Cardiovasc Interv. 2016 Mar;87(4):797-804. Courtesy of Dr. Carlos Fava. Approximately 10 to 13% of low-flow low-gradient severe aortic stenosis cases (LF-LG) have preserved left ventricular function. Its physiopathology remains unclear and it has been associated with a...
TAVI: Good Outcomes with Intermediate Risk
Original Title: Transcatheter Aortic Valve Replacement versus Surgical Valve Replacement in Intermediate-Risk Patients: A Propensity Score Analysis. Reference: Vinod H Thourani et al. Lancet Published Online April 3, 2016. Courtesy of Dr. Carlos Fava. The transcatheter Aortic Valve Replacement (TAVI) has shown benefits in high risk patients or inoperable patients, but there is little evidence...
CoreValve US Pivotal: at 3 Years, the Self-Expanding Valve Maintains Its Advantage vs. Surgery
At 3 year follow up, the CoreValve US Pivotal study on high risk elderly patients, the self-expanding valve showed a lasting benefit vs. surgery. These findings could suggest that the self-expanding valve should be considered the preferred treatment in patients with symptomatic severe aortic stenosis at increased risk for surgery. The study included 797 patients...
One year outcomes of the new repositionable and retrievable valve
Original Title: 1-Year Outcomes with the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients with Severe Aortic Stenosis Results of the REPRISE II Study. Reference: Ian T. Meredith et al. J Am Coll Cardiol Intv. 2016;9(4):376-384. This analysis represents the first report at one year of 120 patients enrolled...
TAVI in patients older than 90: similar outcomes to those obtained in younger patients
Original title: Comparison of Outcomes of Transcathether Aortic Valve Implantation in Patients ≥90 Years Versus <90 Years. Reference: Yigal Abramowitz, et al. Am J Cardiol 2015;116:1110-1115. More and more 90 year old patients require transcatheter aortic valve replacement (TAVI); however, its benefits have not been studied in this particular population. This study enrolled 734 patients...
SAPIENS 3: Favorable outcomes with TAVI in intermediate risk patients
Transcatheter aortic valve replacement is a safe and effective alternative to surgery in patients with severe aortic stenosis and high surgical risk as the 5-year results of PARTNER 1 Alternate showed. The aim of this study was to evaluate the result of the Edwards Sapien 3 valve in patients with severe aortic stenosis and intermediate...
PARTNER to 5 years. TAVR is an effective alternative to surgery in high risk patients
This study included 699 patients with severe aortic stenosis and high surgical risk of whom 348 received transcatheter aortic valve replacement (TAVR) and 351 received surgery. Previous reports of the results to one, two and three years and this work published simultaneously in Lancet reports the final follow-up at 5 years. The mortality at follow-up...
US CoreValve: Cost effectiveness of transcatheter replacement versus surgical replacement in high-risk patients
Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR). There is little consensus regarding the cost-effectiveness for transcatheter versus surgical replacement. The present study was aimed to quantify the quality of life, adjusted survival for quality of life, resource utilization,...
CoreValve US Pivotal Trial: 2-year results of the self-expanding valve on inoperable patients
This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery. The primary end point was a composite of all-cause mortality and stroke at 24 months. The rate of death from any cause or cerebrovascular accident at 24 months was 38% for...
UK TAVI Registry: Long-term results of TAVI in the UK
This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than 4500 patients with 100% follow-up for mortality. The 3-year mortality was 61.6 % beyond the device or path. Atrial fibrillation, renal failure, chronic obstructive pulmonary disease and a EuroSCORE > 18.5...